Skip to main content
Top
Published in: International Journal of Clinical Oncology 4/2015

01-08-2015 | Original Article

Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma

Authors: Yoichi Fujii, Masaomi Ikeda, Kazuhiro Kurosawa, Mariko Tabata, Takayuki Kamigaito, Chihiro Hosoda, Toshikazu Okaneya

Published in: International Journal of Clinical Oncology | Issue 4/2015

Login to get access

Abstract

Background

To evaluate the clinicopathological features and identify predictive factors in patients with early and late recurrence following initial surgery for localized renal cell carcinoma.

Methods

From April 1988 to January 2013, 486 patients without metastases at the initial diagnosis underwent either radical nephrectomy or partial nephrectomy and were followed up thereafter. Patients were divided into 3 groups; no recurrence, early recurrence (recurrence within 5 years), and late recurrence (recurrence after 5 years). Cancer-specific survival after recurrence was analyzed by using the Kaplan–Meier method. Multivariate logistic regression analysis was applied to define clinical and pathological factors correlated to early and late recurrence following surgery.

Results

Seventy-seven (15.8 %) and 18 (3.7 %) patients developed early and late recurrence, respectively. In multivariate logistic regression analysis, positive symptoms at diagnosis, ≥pT2, positive lymphovascular invasion, and grade 3 were independent predictive factors for early recurrence. Age at surgery and ≥pT2 were significantly correlated to late recurrence. The 5-year cancer-specific survival rate after recurrence was 72.4 and 52.9 % in the late and the early recurrence groups, respectively (P = 0.044).

Conclusions

The risk factors for clinical recurrence differed according to the time that had elapsed between initial surgery and the first metastasis in patients with localized renal cell carcinoma. Our study showed age at initial surgery and the pT stage were independent predictive factors for late recurrence. Further investigation of a larger number of patients is required to predict which patients may develop recurrence in the future and to choose appropriate treatment.
Literature
1.
go back to reference Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406PubMedCrossRef Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406PubMedCrossRef
2.
go back to reference Hollingsworth JM, Miller DC, Daignault S et al (2007) Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109:1763–1768PubMedCrossRef Hollingsworth JM, Miller DC, Daignault S et al (2007) Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109:1763–1768PubMedCrossRef
3.
go back to reference Nguyen MM, Gill IS, Ellison LM (2006) The evolving presentation of renal carcinoma in the United States: trends from the surveillance, epidemiology, and end results program. J Urol 176:2397–2400PubMedCrossRef Nguyen MM, Gill IS, Ellison LM (2006) The evolving presentation of renal carcinoma in the United States: trends from the surveillance, epidemiology, and end results program. J Urol 176:2397–2400PubMedCrossRef
4.
go back to reference Kim SP, Weight CJ, Leibovich BC et al (2011) Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 78:1101–1106PubMedCrossRef Kim SP, Weight CJ, Leibovich BC et al (2011) Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 78:1101–1106PubMedCrossRef
5.
go back to reference Ljungberg B, Alamdari FI, Rasmuson T et al (1999) Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84:405–411PubMedCrossRef Ljungberg B, Alamdari FI, Rasmuson T et al (1999) Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84:405–411PubMedCrossRef
6.
go back to reference Nakano E, Fujioka H, Matsuda M et al (1984) Late recurrence of renal cell carcinoma after nephrectomy. Eur Urol 10:347–349PubMed Nakano E, Fujioka H, Matsuda M et al (1984) Late recurrence of renal cell carcinoma after nephrectomy. Eur Urol 10:347–349PubMed
7.
go back to reference Gelb AB (1997) Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:981–986PubMedCrossRef Gelb AB (1997) Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:981–986PubMedCrossRef
8.
go back to reference Thrasher JB, Paulson DF (1993) Prognostic factors in renal cancer. Urol Clin North Am 20:247–262PubMed Thrasher JB, Paulson DF (1993) Prognostic factors in renal cancer. Urol Clin North Am 20:247–262PubMed
9.
go back to reference Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474PubMedCrossRef Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474PubMedCrossRef
10.
go back to reference Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284PubMedCrossRef Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284PubMedCrossRef
11.
go back to reference Naumov GN, Folkman J, Straume O (2009) Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis 26:51–60PubMedCrossRef Naumov GN, Folkman J, Straume O (2009) Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis 26:51–60PubMedCrossRef
12.
go back to reference Husemann Y, Geigl JB, Schubert F et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68PubMedCrossRef Husemann Y, Geigl JB, Schubert F et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68PubMedCrossRef
13.
go back to reference Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533PubMedCrossRef Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533PubMedCrossRef
14.
go back to reference Brookman-May S, May M, Shariat SF et al (2013) Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN project). Eur Urol 64:472–477PubMedCrossRef Brookman-May S, May M, Shariat SF et al (2013) Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN project). Eur Urol 64:472–477PubMedCrossRef
15.
go back to reference Park YH, Baik KD, Lee YJ et al (2012) Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU Int 110:553–558CrossRef Park YH, Baik KD, Lee YJ et al (2012) Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU Int 110:553–558CrossRef
16.
go back to reference Adamy A, Chong KT, Chade D et al (2011) Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 185:433–438PubMedCrossRef Adamy A, Chong KT, Chade D et al (2011) Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 185:433–438PubMedCrossRef
17.
go back to reference Uchida K, Miyao N, Masumori N et al (2002) Recurrence of renal cell carcinoma more than 5 years after nephrectomy. Int J Urol 9:19–23PubMedCrossRef Uchida K, Miyao N, Masumori N et al (2002) Recurrence of renal cell carcinoma more than 5 years after nephrectomy. Int J Urol 9:19–23PubMedCrossRef
18.
go back to reference Kyoda Y, Kobayashi K, Hirobe M et al (2014) Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment. Int J Clin Oncol 19:146–151PubMedCrossRef Kyoda Y, Kobayashi K, Hirobe M et al (2014) Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment. Int J Clin Oncol 19:146–151PubMedCrossRef
19.
go back to reference Kavolius JP, Mastorakos DP, Pavlovich C et al (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261–2266PubMed Kavolius JP, Mastorakos DP, Pavlovich C et al (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261–2266PubMed
20.
go back to reference Maldazys JD, deKernion JB (1986) Prognostic factors in metastatic renal carcinoma. J Urol 136:376–379PubMed Maldazys JD, deKernion JB (1986) Prognostic factors in metastatic renal carcinoma. J Urol 136:376–379PubMed
21.
go back to reference Kroeger N, Choueiri TK, Lee JL et al (2014) Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 65:1086–1092PubMedCrossRef Kroeger N, Choueiri TK, Lee JL et al (2014) Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 65:1086–1092PubMedCrossRef
22.
go back to reference Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
23.
go back to reference Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef
24.
go back to reference Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939PubMedCrossRef Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939PubMedCrossRef
25.
go back to reference Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef
26.
go back to reference Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRef Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRef
27.
go back to reference Levy DA, Slaton JW, Swanson DA et al (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163–1167PubMedCrossRef Levy DA, Slaton JW, Swanson DA et al (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163–1167PubMedCrossRef
28.
go back to reference Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef
Metadata
Title
Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma
Authors
Yoichi Fujii
Masaomi Ikeda
Kazuhiro Kurosawa
Mariko Tabata
Takayuki Kamigaito
Chihiro Hosoda
Toshikazu Okaneya
Publication date
01-08-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-014-0775-2

Other articles of this Issue 4/2015

International Journal of Clinical Oncology 4/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine